Volitinib, a potent and highly selective c‐Met inhibitor, effectively blocks c‐Met signaling and growth in c‐MET amplified gastric cancer patient‐derived tumor xenograft models
Paul R. Gavine(Johnson & Johnson (United States)), Q. May Wang
Cited by 120
Related Papers
JNJ-79032421, a Novel Membrane-Restricted Mesothelin-Targeting T Cell–Engaging Bispecific Antibody for the Treatment of Mesothelin-Positive Cancers
|Molecular Cancer Therapeutics|2026|0